vs
Side-by-side financial comparison of Doximity, Inc. (DOCS) and PTC THERAPEUTICS, INC. (PTCT). Click either name above to swap in a different company.
Doximity, Inc. is the larger business by last-quarter revenue ($185.1M vs $164.7M, roughly 1.1× PTC THERAPEUTICS, INC.). Doximity, Inc. runs the higher net margin — 33.3% vs -82.0%, a 115.2% gap on every dollar of revenue. On growth, Doximity, Inc. posted the faster year-over-year revenue change (9.8% vs -22.7%). Over the past eight quarters, Doximity, Inc.'s revenue compounded faster (25.2% CAGR vs -11.5%).
Doximity is an online networking service for medical professionals. Launched in 2010, the platform offers its members curated medical news, telehealth tools, and case collaboration.
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
DOCS vs PTCT — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $185.1M | $164.7M |
| Net Profit | $61.6M | $-135.0M |
| Gross Margin | 89.9% | — |
| Operating Margin | 38.9% | -43.3% |
| Net Margin | 33.3% | -82.0% |
| Revenue YoY | 9.8% | -22.7% |
| Net Profit YoY | -18.1% | -104.8% |
| EPS (diluted) | $0.31 | $-1.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $185.1M | $164.7M | ||
| Q3 25 | $168.5M | $211.0M | ||
| Q2 25 | $145.9M | $178.9M | ||
| Q1 25 | $138.3M | $1.2B | ||
| Q4 24 | $168.6M | $213.2M | ||
| Q3 24 | $136.8M | $196.8M | ||
| Q2 24 | $126.7M | $186.7M | ||
| Q1 24 | $118.1M | $210.1M |
| Q4 25 | $61.6M | $-135.0M | ||
| Q3 25 | $62.1M | $15.9M | ||
| Q2 25 | $53.3M | $-64.8M | ||
| Q1 25 | $62.5M | $866.6M | ||
| Q4 24 | $75.2M | $-65.9M | ||
| Q3 24 | $44.2M | $-106.7M | ||
| Q2 24 | $41.4M | $-99.2M | ||
| Q1 24 | $40.6M | $-91.6M |
| Q4 25 | 89.9% | — | ||
| Q3 25 | 90.3% | — | ||
| Q2 25 | 89.2% | — | ||
| Q1 25 | 89.5% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 90.0% | — | ||
| Q2 24 | 89.3% | — | ||
| Q1 24 | 89.4% | — |
| Q4 25 | 38.9% | -43.3% | ||
| Q3 25 | 37.8% | 1.4% | ||
| Q2 25 | 37.4% | -19.5% | ||
| Q1 25 | 35.2% | 82.5% | ||
| Q4 24 | 47.4% | -76.2% | ||
| Q3 24 | 38.8% | -27.7% | ||
| Q2 24 | 36.4% | -21.5% | ||
| Q1 24 | 35.5% | -21.6% |
| Q4 25 | 33.3% | -82.0% | ||
| Q3 25 | 36.8% | 7.5% | ||
| Q2 25 | 36.5% | -36.3% | ||
| Q1 25 | 45.2% | 73.7% | ||
| Q4 24 | 44.6% | -30.9% | ||
| Q3 24 | 32.3% | -54.2% | ||
| Q2 24 | 32.7% | -53.1% | ||
| Q1 24 | 34.4% | -43.6% |
| Q4 25 | $0.31 | $-1.63 | ||
| Q3 25 | $0.31 | $0.20 | ||
| Q2 25 | $0.27 | $-0.83 | ||
| Q1 25 | $0.31 | $10.04 | ||
| Q4 24 | $0.37 | $-0.85 | ||
| Q3 24 | $0.22 | $-1.39 | ||
| Q2 24 | $0.21 | $-1.29 | ||
| Q1 24 | $0.20 | $-1.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $64.8M | $1.9B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $979.3M | $-205.3M |
| Total Assets | $1.2B | $2.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $64.8M | $1.9B | ||
| Q3 25 | $169.2M | $1.7B | ||
| Q2 25 | $137.3M | $2.0B | ||
| Q1 25 | $209.6M | $2.0B | ||
| Q4 24 | $165.3M | $1.1B | ||
| Q3 24 | $184.2M | $1.0B | ||
| Q2 24 | $111.4M | $1.1B | ||
| Q1 24 | $96.8M | $884.8M |
| Q4 25 | $979.3M | $-205.3M | ||
| Q3 25 | $1.1B | $-155.8M | ||
| Q2 25 | $1.0B | $-206.5M | ||
| Q1 25 | $1.1B | $-185.8M | ||
| Q4 24 | $1.0B | $-1.1B | ||
| Q3 24 | $961.2M | $-1.1B | ||
| Q2 24 | $913.6M | $-980.2M | ||
| Q1 24 | $901.4M | $-893.9M |
| Q4 25 | $1.2B | $2.9B | ||
| Q3 25 | $1.3B | $2.6B | ||
| Q2 25 | $1.2B | $2.6B | ||
| Q1 25 | $1.3B | $2.7B | ||
| Q4 24 | $1.2B | $1.7B | ||
| Q3 24 | $1.1B | $1.8B | ||
| Q2 24 | $1.1B | $1.9B | ||
| Q1 24 | $1.1B | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $60.9M | $-34.3M |
| Free Cash FlowOCF − Capex | — | $-36.6M |
| FCF MarginFCF / Revenue | — | -22.3% |
| Capex IntensityCapex / Revenue | — | 1.4% |
| Cash ConversionOCF / Net Profit | 0.99× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $702.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.9M | $-34.3M | ||
| Q3 25 | $93.9M | $-66.3M | ||
| Q2 25 | $62.1M | $-58.3M | ||
| Q1 25 | $98.5M | $870.1M | ||
| Q4 24 | $65.2M | $-30.0M | ||
| Q3 24 | $68.3M | $-77.0M | ||
| Q2 24 | $41.2M | $-71.5M | ||
| Q1 24 | $63.9M | $70.8M |
| Q4 25 | — | $-36.6M | ||
| Q3 25 | — | $-69.7M | ||
| Q2 25 | — | $-59.6M | ||
| Q1 25 | — | $868.4M | ||
| Q4 24 | — | $-33.8M | ||
| Q3 24 | — | $-77.5M | ||
| Q2 24 | — | $-78.8M | ||
| Q1 24 | — | $61.2M |
| Q4 25 | — | -22.3% | ||
| Q3 25 | — | -33.1% | ||
| Q2 25 | — | -33.3% | ||
| Q1 25 | — | 73.8% | ||
| Q4 24 | — | -15.8% | ||
| Q3 24 | — | -39.4% | ||
| Q2 24 | — | -42.2% | ||
| Q1 24 | — | 29.1% |
| Q4 25 | — | 1.4% | ||
| Q3 25 | — | 1.6% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | 0.0% | 0.1% | ||
| Q4 24 | 0.0% | 1.8% | ||
| Q3 24 | 0.0% | 0.3% | ||
| Q2 24 | 0.0% | 4.0% | ||
| Q1 24 | 0.0% | 4.6% |
| Q4 25 | 0.99× | — | ||
| Q3 25 | 1.51× | -4.17× | ||
| Q2 25 | 1.16× | — | ||
| Q1 25 | 1.58× | 1.00× | ||
| Q4 24 | 0.87× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.00× | — | ||
| Q1 24 | 1.57× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
PTCT
Segment breakdown not available.
